Position Statements
Date Posted: 01 - June - 2015
Date Posted: 16 - November - 2022
BNF chapter:
Immune system and Malignant Disease
Expand/Collapse
Where a proprietary biological medicine is indicated and biologically similar (biosimilar) medicine(s) to the reference product also exist the product with the lowest acquisition price should be used and charged to the commissioning organisation at the acquisition price (within licensed indications).
Product choices, including changes to treatment, for individual patients should be made following assessment by the responsible clinician taking into account patient choice.